1-(2-chloro-4-phenylethynylbenzyl)-2-methyl-6-(1-pentanesulfonylcarbamoyl)benzimidazole | 219571-65-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(2-chloro-4-phenylethynylbenzyl)-2-methyl-6-(1-pentanesulfonylcarbamoyl)benzimidazole
• 英文别名: 3-[[2-chloro-4-(2-phenylethynyl)phenyl]methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide
• CAS: 219571-65-0
• 化学式: C₂₉H₂₈ClN₃O₃S
• 分子量: 534.079
• InChiKey: FZAFLXKCHMXNMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  89.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• BENZIMIDAZOLE DERIVATIVES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1020452A1

  公开（公告）日：2000-07-19

  A novel benzimidazole derivative or a salt thereof is provided, which is represented by the formula: wherein R1 represents an alkyl group, etc., R2 represents a substituted or unsubstituted aromatic lower alkyl group, R3 represents an alkyl group, etc., and -X- is represented by the following formula (V): etc. This derivative or a salt thereof is useful as medicine.

  本发明提供了一种新型苯并咪唑衍生物或其盐，由式表示： 其中 R1 代表烷基等，R2 代表取代或未取代的芳香族低级烷基，R3 代表烷基等，-X- 由下式（V）表示： 等。这种衍生物或其盐可用作药物。
• Concomitant drugs
  申请人：Kayakiri Hiroshi

  公开号：US20050197376A1

  公开（公告）日：2005-09-08

  This invention provides a pharmaceutical agent containing, in combination, a sulfonamide compound and other therapeutic agent, preferably, at least one compound represented by the formula (I): R 1 —SO 2 —NH—CO-A 1 -CH 2 —R 2 [each symbol is as defined in the specification] or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical agent selected from the group consisting of an α-glucosidase inhibitor, an insulin secretagogue, a sulfonylurea and a biguanide, which has a superior therapeutic effect.

  本发明提供了一种药物制剂，其中含有磺酰胺化合物和其他治疗剂，最好是至少一种由式 (I) 代表的化合物：R 1 -SO 2 -NH-CO-A 1 -CH 2 -R 2 [各符号如说明书中所定义]或其药学上可接受的盐，以及至少一种选自α-葡萄糖苷酶抑制剂、胰岛素促泌剂、磺酰脲类和双胍类的药剂，这些药剂具有更好的治疗效果。
• US6420409B1
  申请人：——

  公开号：US6420409B1

  公开（公告）日：2002-07-16
• [EN] CONCOMITANT DRUGS<br/>[FR] MÉDICAMENTS ASSOCIÉS
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2005082414A2

  公开（公告）日：2005-09-09

  This invention provides a pharmaceutical agent containing, in combination, a sulfonamide compound and other therapeutic agent, preferably, at least one compound represented by the formula (I): R1-SO2-NH-CO-A1-CH2-R2 [each symbol is as defined in the specification] or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical agent selected from the group consisting of an α-glucosidase inhibitor, an insulin secretagogue, a sulfonylurea and a biguanide, which has a superior therapeutic effect.